Technology | Virtual and Augmented Reality | June 04, 2019

Ann Arbor Startup Launches Augmented Reality MRI Simulator

SpellBound’s MRI Simulator reduces sedation rates and acclimates pediatric patients for MRIs in a fun, interactive way

Ann Arbor Startup Launches Augmented Reality MRI Simulator

June 4, 2019 — SpellBound, an Ann Arbor startup specializing in augmented reality (AR) tools for children in hospitals, has officially launched their AR MRI Simulator to market. SpellBound’s MRI Simulator is designed to reduce the high sedation rates for pediatric magnetic resonance imaging (MRI) scans by acclimating children to the experience in a way that is fun and interactive.

The blaring noises, tight spaces and unfamiliar environment of an MRI are often what produce fear and anxiety in children. The MRI Simulator eases these fears by familiarizing children with the process of an MRI, allowing them to walk through the procedure so they feel comfortable when the time comes for their appointment. SpellBound’s MRI simulator is accessible on smartphones and tablets, giving children and their caregivers the opportunity to engage with the simulator in the comfort of their own homes.

The inspiration for the simulator originated from feedback SpellBound has gathered from parents and clinicians who work with children struggling with MRIs. Christina York, CEO of SpellBound, said that it was particularly driven by the frustration families and hospital staff have around unnecessary sedation.

SpellBound’s MRI Simulator is ready to integrate into patient education programs and improve patient experience with the MRI.

For more information: www.spellboundar.com

Related Pediatric MRI Content

VIDEO: MRI Mobile Experience Apps for Kids

Pediatric MRI Calming Techniques

Related Content

ADHD Medication May Affect Brain Development in Children

Images of regions of interest (colored lines) in the white matter skeleton representation. Data from left and right anterior thalamic radiation (ATR) were averaged. Image courtesy of C. Bouziane et al.

News | Neuro Imaging | August 16, 2019
A drug used to treat attention-deficit/hyperactivity disorder (ADHD) appears to affect development of the brain’s...
Profound Medical Receives U.S. FDA 510(k) Clearance for Tulsa-Pro
Technology | Interventional Radiology | August 16, 2019
Profound Medical Corp. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to...
RSNA and ACR to Collaborate on Landmark Medical 3D Printing Registry
News | Medical 3-D Printing | August 08, 2019
The Radiological Society of North America (RSNA) and the American College of Radiology (ACR) will launch a new medical...
Synaptive Medical Launches Modus Plan With Automated Tractography Segmentation
Technology | Neuro Imaging | August 07, 2019
Synaptive Medical announced the U.S. launch and availability of Modus Plan featuring BrightMatter AutoSeg. This release...
Canon Medical Introduces Encore Orian MR Upgrade Program
News | Magnetic Resonance Imaging (MRI) | August 06, 2019
Canon Medical Systems USA Inc. is helping to provide low-cost patient care solutions for its customers with the launch...
DrChrono Teams With DeepScribe to Automate Medical Note Taking in EHR
News | Electronic Medical Records (EMR) | August 01, 2019
DrChrono Inc. and DeepScribe announced a partnership so medical practices using DrChrono EHR can use artificial...
FDA Issues Draft Guidance on Medical Device Safety in MRI Environment
News | Magnetic Resonance Imaging (MRI) | August 01, 2019 | Jeff Zagoudis, Associate Editor
The U.S. Food and Drug Administration (FDA) issued a new draft guidance titled Testing and Labeling Medical Devices for...
Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Feature | Contrast Media | July 18, 2019 | By Greg Freiherr
Macrocyclic contrast agents have the best safety profile of all the magnetic resonance (MR) contrast media that are n
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...